Capsule Endoscopic Devices

The device is ingested similar to other existing capsule endoscopic devices in accordance with current clinical practice. Once the device is initiated, it will start detecting immediately using optical technology and can be used to monitor the presence of UGIB for a period up to 3 days. The data is wirelessly transmitted to an external monitor (PC, mobile phone, custom receiver, etc.) enabling a real-time diagnosis. The IP was originally developed in Harvard University and was enhanced by the EnteraSense team. It will alleviate the need for patients to undergo unnecessary procedures and ensure prompt diagnoses and correct treatment. With a potential reduction of unnecessary endoscopies, the Health Economics benefits to the hospital and insurance companies are significant.